SIGA's Business Model
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security and infectious disease markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. SIGA Technologies, Inc. has a strategic partnership with Cipla Therapeutics to deliver sustained innovation and access to antibacterial drugs primarily against biothreats. The company was incorporated in 1995 and is headquartered in New York, New York.
| Sector & Industry | Healthcare / Drug Manufacturers - Specialty & Generic |
| Website | https://www.siga.com |
| CEO (Chief Executive Officer) | Diem Nguyen |
| Number of Employees | |
| IPO date | September 10, 1997 |
SIGA Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 31 East 62nd Street |
| City | New York City |
| State | NY |
| Phone | 212 672 9100 |
| Zip Code | 10065 |
| Other Identifiers | |
| CIK | 0001010086 |
| ISIN | US8269171067 |
| CUSIP | 826917106 |
| Open | 6.8 |
| Previous Close | 6.85 |
| Volume | 291.6 Thou. |
| Average Volume | 380.5 Thou. |
| Day’s Range | 6.655 – 6.83 |
| 52 Week Range | 4.95-9.62 |
| MA (50) | 6.581 |
| MA (200) | 6.9949 |
| Market Cap | 484.8 Mil. |
| Shares Out. | 71.61 Mil. |
| Earnings Date | Feb 26, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
Industry Competitors for SIGA
|
Company
|
PE Ratio | Market Cap |
|---|---|---|
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
||
|
|
